EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
47 hedge funds and large institutions have $120M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
600% more capital invested
Capital invested by funds: $17.2M → $120M (+$103M)
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
96% more funds holding
Funds holding: 24 → 47 (+23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$21M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$14.8M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$12.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$168K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$145K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$57K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16.8K |
EPRS Hedge Fund Activity: Q1 2015 in Review
47 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q1 2015, worth a combined $120M — up 600% from $17.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new EPRS positions and 5 closed out — a net gain of 23 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $21M. The largest seller was Renaissance Technologies, cutting an estimated $168K.
- 47 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q1 2015, up from 24 in Q4 2014.
- Funds reported $120M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q1 2015, up 600% quarter-over-quarter.
- 28 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q1 2015 and 5 closed out, a net change of +23 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q1 2015 was Jennison Associates, an estimated $21M added.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q1 2015 was Renaissance Technologies, an estimated $168K sold.
Based on aggregated 13F filings for Q1 2015.